3 Stocks Under $10 You Need to Watch

A low per-share price doesn’t necessarily make a stock “cheap.” Much can depend on the number of outstanding shares and other factors. 

However, with stocks under $10, there is often more room to grow and room for larger returns.

The problem? There are plenty of stocks under $10, but many of them aren’t worth your time.

However, there are absolutely gems if you know where to look.

That’s where the Zen Ratings system comes in. This review of 115 factors proven to drive stock growth can help you sift through the many options and find the highest-quality contenders.

Recently, we developed a new way to leverage our ratings system with Zen Strategies — a collection of portfolios with different themes to suit different investors. The “Under $10 Stocks” portfolio is one of our most popular offerings so far. 

Here’s a sampling of the high-caliber under-$10 stocks with solid fundamentals you might find in the portfolio: 

A note from our sponsors...
Trade Alert: Your First Two (Money Doubling?) Trades  

Jim Fink is about to issue two brand new trades designed to double their money (or more) in 3 to 10 days... and you're invited to get in on the action. I would caution you not to overlook this opportunity... Over the last 10 years (through multiple downturns) Jim has closed out 97% of his recommendations "in the green." His next two trades go live soon... if you want in you should make a move NOW.  

Claim your first two trades here.

1. Infusystem Holdings (NYSEMKT: INFU)

Infusion pumps might seem like a niche business (and it is), but it doesn’t mean it is a bad business or that INFU isn’t a stock worth taking a closer look at. In fact, the fact that it doesn’t operate across the country yet only highlights room for growth.

While the Momentum Component Grade isn’t strong, consider the investor sentiment behind it or its potential for growth in the years to come. And while it does not have as much coverage as most other stocks, the coverage that is available from analysts provides a rather high price target, ranging from $13 in the past to a more recent $12 (nearly double INFU’s current price).

2. Puma Biotechnology (NASDAQ: PBYI)

Focusing primarily on cancer care in the United States and beyond, PBYI is a biopharmaceutical company with potentially promising drug candidates, some of which have already completed initial clinical testing. Effective cancer therapies and treatments reaching the commercial stage would have the potential to launch PBYI to new heights.

It is regularly considered undervalued, and it has a solid financial foundation, as evidenced by its Financials Component Grade of A. While the share price has declined by 10.31% over the past year, and it had reached much greater heights years ago, this is not indicative of the potential PBYI has for investors who are willing to wait or find promise in the company, provided they are comfortable taking on some risk in the process.

A note from our sponsors...
Big Data gold rush: $PLTR passes $400B. $MODE prepares  

Palantir grew 900% in 2 years. Mode Mobile? A staggering 32,481% in 3 years—ranking it North America's fastest-growing software company.  
While Palantir profits off your data, Mode lets you cash in. Over 50M users have already earned or saved $325M just by using their phones.  
Walmart and Best Buy carry their devices. Nasdaq ticker $MODE secured. And now, you can get in before a potential IPO at just $0.30/share.  
The next data giant isn't just helping corporations—it's helping you.  

Pre-IPO offer closing - claim your piece of the $MODE now.
  

Disclosure: Mode Mobile recently received their ticker reservation with Nasdaq ($MODE), indicating an intent to IPO in the next 24 months. An intent to IPO is no guarantee that an actual IPO will occur. Please read the offering circular and related risks at invest.modemobile.com.  

3. Udemy (NASDAQ: UDMY)

Udemy provides access to tens of thousands of courses to customers on both the enterprise and individual levels in dozens of languages, having a global reach and an expanding model. Despite that, as of this writing, the share price is only $7.53.

For its Component Grades, it scores a B for Growth, Sentiment, and Financials. Investors see room for growth in UDMY, and the fundamentals support this view. It also helps that earnings and revenues reports last week surpassed estimates, leading to a share price gain over the last week.

Want more information on all of these stocks and more, and want to track them more easily? Then WallStreetZen Premium is for you. With it, you’ll get all the fundamental information you need, an unlimited watchlist, and more. It’s perfect for keeping a close eye on stocks with strong potential that could grow in the blink of an eye.

Looking for a more guided approach on top of good information? Check out Zen Strategies — your fast-forward button to locating the highest-potential stocks across a variety of themes in minutes per month. 

What to Do Next?

• 9 Special Stock Lists You Need Now >
• See All “A” Rated Stocks with +32.52% Average Annual Return >
• 2 New Stocks to Buy from Steve Reitmeister >

Want to get in touch? Email us at news@wallstreetzen.com.